Does The Surfactant Administration by Aerosolization Effective?

• Status: Unknown status
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study was designed to evaluate, in premature babies with RDS breathing spontaneously, the efficacy of combined treatment with nasal continuous positive airway pressure (CPAP) and aerosolized surfactant. The first objective of investigators is to assess the safety of surfactant nebulization in this clinical situation, and to find out whether treatment with aerosolized surfactant would reduce the need for mechanical ventilation. And other aim suggest that aerosolized dates compared with dates of INSURE (intubation-surfactant-extubation) and minimally invasive surfactant therapy (MIST) method.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: nihat demir
• Treatments: Pulmonary Surfactants

Criteria

Inclusion Criteria:

• Corrected gestational age >26 week or <34 week,

• Age 2-36 h

• Clinically and radiologically diagnosed progressive RDS,

• FiO2 needed to maintain SaO2 85-95%; >0.4

• No evident lung or cardiovascular malformation.

Exclusion Criteria:

• Corrected gestational age <26 week or >34 week,

• Age >36 h

• Premature babies with RDS but no breathing spontaneously

• Evident lung or cardiovascular malformation.